Zoz, Donald F.
Boehringer Ingelheim (United States)
3 papers on CoChat
Most cited papers
- Verified
Nerandomilast in Patients with Idiopathic Pulmonary Fibrosis.
Richeldi, L., Azuma, A., Cottin, V., Kreuter, M., Maher, T. M., Martinez, F. J., Oldham, J. M., Valenzuela, C., Clerisme-Beaty, E., Gordat, M., et al. (2025) · New England Journal of Medicine
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPulmonary Hypertension Research and Treatments
Cited by 297
- Verified
Trial of a Preferential Phosphodiesterase 4B Inhibitor for Idiopathic Pulmonary Fibrosis
Richeldi, L., Azuma, A., Cottin, V., Hesslinger, C., Stowasser, S., Valenzuela, C., Wijsenbeek, M. S., Zoz, D. F., Voss, F., & Maher, T. M. (2022) · New England Journal of Medicine
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPhosphodiesterase function and regulation
Cited by 236
- Verified
Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis
Maher, T. M., Schlecker, C., Luedtke, D., Bossert, S., Zoz, D. F., & Schultz, A. (2022) · ERJ Open Research
Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisPhosphodiesterase function and regulation
Cited by 26
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free